Sunday, February 26, 2012

News and Events - 27 Feb 2012




25.02.2012 14:07:00


The head of Britain biggest drugs company has accused the Government of systematically delaying the introduction of new cancer drugs in order to save money.

GLaxoSmithKline chief executive Sir Andrew Witty warned that ministers were making false economies as they tried to grapple with the deficit in the public finances.

In an interview with the BBC, he said that governments across Europe had already cut drug prices by 5% a year - costing GSK around ?300 million per annum.

However, he said governments were now seeking to go further in an effort to achieve even bigger savings - and he highlighted Britain's decision to delay new cancer treatments.

"The bit I'm much more frightened about is that what's now beginning to become clear is that, in addition to price reductions, governments are delaying the approval of innovative new drugs," he said.

"So a second way they can save money, they think, is 'Let's just not buy the next round of innovation'.

"Cancer in the UK is a good example where we're seeing oncology drugs being systematically delayed from introduction and reimbursement.

"We are seeing a variety of the more innovative and more expensive medicines being delayed in a whole series of different diseases across Europe."

Sir Andrew accused governments of treating the pharmaceuticals industry as a "simple procurement business" without understanding the wider implications of their decisions.

"As governments have got more and more anxious about their debt positions and austerity agendas, what happened is quite predictable," he said.

"If you are a minister and you need to cut costs, it is a lot easier to cut drug prices than it is to close a hospital or reduce the size of the Civil Service. I understand that.

"The issue here is, of course, if you don't buy the new drug it is going to save you money in the drug bill. But the drug bill is only 8% to 10% of the total healthcare bill and what is being lost in this stampede for cost cut is any kind of strategic thoughtfulness."

Permalink |
Leave a comment  »




25.02.2012 13:44:12
- AMIA Summits on Translational Science proceedings AMIA Summit on Translational Science
- BMC Medical Genomics
- Briefings in Functional Genomics
- Clinical Proteomics
- Computational and Mathematical Methods in Medicine
- Epigenomics
- Expert Review of Proteomics
- G3
- Genome Medicine
- GMS Current Topics in Computer and
- Healthcare Informatics Research
- IEEE Transactions on Information Technology in Biomedicine
- IEEE Transactions on Nanobioscience
- Interdisciplinary Sciences: Computational Life Sciences
- International Journal of Proteomics
- Journal of Ocular Biology, Diseases, and Informatics
- Journal of Proteomics
- OMICS: A Journal of Integrative Biology
- Pacific Symposium on Biocomputing
- Proteomics. Clinical Applications
- Standards in Genomic Sciences
- Systems and Synthetic Biology
- Systems Biology in Reproductive Medicine
- The HUGO Journal
- The Pharmacogenomics Journal
- Translational Oncogenomics
- Wiley Interdisciplinary Reviews: Systems Biology and Medicine

Friday, February 24, 2012

News and Events - 25 Feb 2012




24.02.2012 18:43:51
Organisation: 


UN Population Fund


Country: 


Burundi


Closing date: 



23 Mar 2012



VACANCY NO.: Job ID 1940

CLOSING DATE: 23 March 2012 (5.00 p.m. New York time

POST TITLE: Technical Specialist (MH/RHCS

CATEGORY: ICS-11 (equivalent to P-4

POST NUMBER: New

DUTY STATION: Bujumbura, Burundi

POST TYPE: Non-Rotational

DURATION: One year (renewable 1/

ORGANIZATIONAL UNIT: Burundi Country Office, ARO

BACKGROUND INFORMATION:

Burundi is one the African Countries where maternal morbidity and mortality is a major health concern. According to results of the last DHS and Census, the maternal mortality ratio (MMR was estimated at 866 deaths per 100000 births. In addition, the health system is registering a weak contraceptive prevalence rate (18% and the presence of a skilled attendant at birth is estimated at 60 percent of the deliveries. The HIV prevalence rate remains high (3,58% with a feminization of the infection (4,02% .

Burundi has suffered repeated waves of intense conflict since independence. Thirteen years of ethnically fuelled civil war have weakened the country’s health care system, including the service provision of reproductive health care system, care for victims of sexual violence and HIV/Aids prevention. Also, as a stream 2 country implementing the RHCS Global Program, the CO will be strongly involved into interventions aiming to strengthen the national health system, the health procurement system through advocacy and Policy Dialogue, technical support including monitoring and evaluation, capacity building, management, coordination partnerships development and knowledge sharing on RHCS.

ORGANIZATIONAL SETTING:

The Technical Specialist post is located in the UNFPA Burundi office in Bujumburae. S/he reports to the Representative, who provides overall direction and supervision, and works in close collaboration with the Johannesburg sub-regional office and the Technical Division. The technical Specialist is part of a team and works in an integrated manner with the programme and operation staff. S/he will ensure technical and programmatic support, in accordance with the principles of result based management and good governance to reinforce the quality of the maternal health programme.

DUTIES AND RESPONSIBILITIES:

The Technical Specialist will have the responsibility for health system strengthening and financing for the promotion, design, monitoring and evaluation, equitable access of RH commodity for all sectors, including supply management system. She/he will provide technical advice and support to RH/FP planners, policy makers, programme managers and service providers on national policies and programmes in the field of Reproductive Health. This will include conducting relevant research, analysis and training to improve knowledge sharing. The incumbent will contribute to an enhancement of national capacity to mobilize and obtain social and political support for national policies and programmes in the field of Reproductive Health.

POLICY, ADVOCACY AND RESOURCE MOBILIZATION

• Provide technical assistance to develop the MDG5 component of the United Nations Development Assistance Framework (UNDAF , the UNFPA Country Programme and annual work plans. • Support national implementing partners in advocacy activities for inclusion of RH/RHCS in SWAPs, PRSPs and health sector reforms • Assist and advise the country office in financial resource mobilization for MNH • Advice the country office and national counterparts on integrated approaches to improve reproductive health, in particular to (i Maternal Health, (ii Family planning (including Condom programming • Reinforce and advise staff and national partners on effective supply chain management, including information management, forecasting, distribution and information systems. • Provide technical assistance to national counterparts in the costing and effective implementation of the national reproductive health action plan. • Assist and advice the country to address the urgent need for skilled health workers, particularly midwives • Assist and advise the country to eliminate obstetric fistula • Assist and advise the country to address the financial barriers to access, especially for the poorest • Provide technical assistance to strengthen the national health information system, and monitoring and evaluation.

CAPACITY DEVELOPMENT AND PARTNERSHIPS

• Maintain and foster partnerships with UN agencies and other partners in the technical area of RH, and RHCS for advancement of knowledge. Carry out joint assessments and projects, formulate recommendations on potential critical maternal health issues and provide advice in respect to MDG targets • Provide technical assistance to national partners to scale-up quality health services to ensure universal access to reproductive health, including family planning, skilled attendance at delivery, emergency obstetric and newborn care • Identify, develop and/or adapt training materials and manuals in substantive areas • Strengthen the capacity of national institutions in the areas of needs assessments, resource mobilisation and monitoring and evaluation

EVIDENCE AND KNOWLEDGE DEVELOPMENT AND DISSEMINATION

? Analysis and synthesis trends and research in the area of RHCS and Maternal Health in Cote d’Ivoire to produce technical knowledge ? Advocate for the incorporation of evaluation results and lessons learned in the updating of strategies and approaches in order to improve the effectiveness of UNFPA operations ? Contribute to the successful execution of impact evaluations. Provide support in developing a prioritized operational research agenda for UNFPA ? Promote UNFPA’s comparative substantive role and specific contribution in the changing development agenda

TECHNICAL REPRESENTATION

? Represent UNFPA on substantive issues and support advocacy for RH, and RHCS in international, governmental, U.N., and other policy and technical meetings and seminars ? Collaborate with UN agencies, academia, professional societies, and act as focal point for inter-agency working groups in the substantive area ? Act as the CO’s focal point for RHCS and Maternal Health. Carry out other duties as may be required by UNFPA Representative.

CORE COMPETENCIES:

? Values/Guiding principles; ? Performance management; ? Developing people/Coaching and Mentoring & Fostering Innovation and Empowerment; ? Working in Teams; ? Self-management/Emotional Intelligence; ? Communication; ? Appropriate and Transparent Decision Making; ? Analytical and Strategic Thinking and Results Orientation/Commitement ot Excellence ? Knowledge Sharing/Continuing Learning

FUNCTIONAL COMPETENCIES:

? Conceptual innovation in the provision of technical expertise ? Leveraging the resources of national governments and partners/Building strategic alliances and partnerships ? Job knowledge/Technical expertise

QUALIFICATIONS:

? Advanced university degree in any of the following - public health, medicine, social sciences, pharmacy, business or other related fields. The degree must be directly related to the substantive area identified in the job description of the post. A course in logistics, essential drugs, health system strengthening and financing and MIS is a plus. ? 7 years of increasing responsibilities in managing RH or health programmes with direct experience relating to supply management systems, of which at least five years national and/or international experience in advising on RH commodities, health systems and supply management. ? Extensive knowledge of supply management: forecasting, warehousing, distribution, transportation and logistics information systems. ? General knowledge of the principles and operational aspects of integrated RH/MH care. ? Familiarity with UN development programmes and working procedures, especially UNFPA policies and programming procedures, an asset. ? Fluency in French. Good command of oral and written English is required.

UNFPA provides a work environment that reflects the values of gender quality, teamwork, respect for diversity, integrity and a healthy balance of work and life. We are committed to maintaining our balanced gender distribution and therefore encourage women to apply.

We offer an attractive remuneration package commensurate with the level of the position. The package includes a competitive salary plus housing allowance, home leave, health insurance and other benefits.

1/ No expectancy of renewal in accordance with UN Staff Regulations 4.5

How to apply: 

UNFPA has established an electronic application management system. This allows applicants to create a candidate profile, which can be updated regularly and submitted for more than one vacancy.

Download the Step by Step Guide to Applying in the E-Recruit System of UNFPA at
http://www.unfpa.org/employment/application_guide.doc. Please print out the Guide for your reference during the registration and application process.

Notice: There is no application, processing or other fee at any stage of the application process. UNFPA does not solicit or screen for information in respect of HIV or AIDS and does not discriminate on the basis of HIV/AIDS status.

Notice to applicants: In accordance with the rules of the United Nations, persons applying to posts in the international Professional category, who hold permanent resident status in a country other than their country of nationality, are required to renounce such status upon their appointment. Exceptions to this rule are very limited and can be made only for: (a stateless persons; (b newly appointed staff members who have applied for citizenship by naturalization, when such citizenship will be granted imminently; (c acting staff members in the General Service and related categories with permanent residency status, on promotion to the Professional category; (d staff members appointed under a temporary appointment. Please understand that UNFPA is not in a position to provide advice on or assistance in applying for any citizenship.

*This is a project-funded post.

http://reliefweb.int/node/478898#comments



25.02.2011 23:14:00

Above is an animated presentation about PatientView's latest report (optimised for Internet Explorer only . Please click on the forward arrow. The Prezi may take 30 seconds to load, so please be patient. Once loaded, to view in fullscreen, click on 'More'.

                           


A global survey of 2,500 patient groups



The report looks at virtually every aspect of doctor-patient relationships (including the role that pharma can play in improving those relationships :


     ·            

Improvements in access to health professionals requested by patients;

·         

Improving the patient information provided by health professionals;

·         

How patients would like doctor-patient communication improved;

·         

Access and choice during diagnosis and treatment—improvements needed by patients
(including a question about the desirable goals of treatment ;

·         

How health professionals can gain patient trust;

·         

How health professionals can respect patients’ valuable time;

·         

How health professionals can be made more accountable (both inside and outside the consulting room ;

·         

How health professionals might improve their prevention practices;

·         

What single action do patients want from government and payers to improve doctor-patient relationships?;

·         

Which pharma companies have a positive record on helping to improve doctor-patient relationships, and why?;

·         

Why pharma can have a negative impact on doctor-patient relationships.

 

The report contains thousands of quotations (arranged by country and by disease from the 2,500 respondent patient groups.

Doctor-patient relations analysed for the following 12 countries and 12



disease areas:

Australia [

number of completed responses = 60

]; Canada [

138

]; Eastern Europe [

105

]; France [

80

]; Germany [

100

]; Italy [

110

]; the Netherlands [

30

]; New Zealand [

55

]; Spain [

80

]; Sweden [

56

]; the UK [

566

]; and the USA [

292

].Cancer

[160

]; diabetes [

55

]; gastro-intestinal [

40

]; heart and circulatory conditions [

70

]; HIV/AIDS [

72

]; mental health [

170

]; multiple sclerosis [

35

]; neurological [

195

]; Parkinson’s disease [

30

]; rare diseases [

70

]; respiratory [

35

]; and rheumatological conditions [

55

]

.

Companies mentioned at least once by respondents:

Abbott / Abbott Diagnostic / Abbott Italia / Actelion Pharmeuticals France / Alcon / Allergan / Amgen / Arthotec / Astellas / AstraZeneca / Baxter / Baxter Healthcare / Bayer / Bayer Schering / Berlin Chemie / Betapharm / Beximco Pharmaceutical Ltd/Bangladesh / Biogen Idec / Boehringer Ingelheim / Bristol Myers Squibb / Celgene / Centocor / Clinuvel / CT Arzneimittel / CT Medicines / Cyberonics Europe / Da Vinci Robotic Surgery System / Desitin / Efalex / Eli Lilly / Esparma / Ferring Pharmaceuticals / Gilead / GSK / Ipsen / Janssen Cilag / Janssen Ortho / Juvela / LEM (Les Entreprise du Médicament / Leo Pharma / Lifescan Italia / London Drug Co in BC / Lundbeck / Medel / Medtronic / Menarini/ Merck / Merck Serono / MSD / Novartis / Novartis Oncology /Novo Nordisk / Nycomed / Ortho McNeil / Permamed / Pfizer / Pharmacy Guild of Australia / Q-pharma / Roche / Roche Diagnostics / Sanofi Aventis / Schering Plough / Servier / Solvay / St Jude / Storz / Stryker / Takeda / Talecris Biotherapeutics/ Temmler / Teva / Teva / Tibotec / UCB Pharma/ Vifor / Worwag Pharma


Profiling patient groups:
The report concludes with a 109-page listing of the profiles of the respondent patient groups from around the world that wished to be named as survey participants.


To find out more about this report:
Please email Alexandra Wyke or Clive Nead


on

info@patient-view.com


 

 

Permalink |
Leave a comment  »




23.02.2012 12:24:00







We Love Pharma, courtesy of CDM Worldwide

The pharmaceutical industry gets a bad rap.  To listen to the critics you’d think pharmaceutical companies are in the same sleazy category as oil, finance and tobacco companies.  But pharmaceutical companies invent life-saving medications, not to mention countless other psychoactive products that many of us enjoy on a recreational basis.  Pharmaceutical companies get blamed for fraud, kickbacks, and research deaths, but they never get the credit for oxycontin.

That is why I was thrilled to see that GlaxoSmithKline is sponsoring the prize for the
British Medical Journal
‘s annual
Research Paper of the Year. Sure, the pharma-bashers will whine like infants at the
BMJ’
s decision to brand a medical research prize with the name of multinational drug company, just as they’re whining about an American editor’s decision to re-locate a leading bioethics journal to the Texas headquarters of a
stem cell tourism clinic. These people just don’t get it.  This is not about propaganda or corruption.  It is about developing innovative medications for diseases that we didn’t even know existed.

In that spirit, my nomination for the GlaxoSmithKline (GSK Research Paper of the Year goes to a ground-breaking article about GSK’s very own antidepressant, Paxil, which was published in the
Journal of the American Academy of Child and Adolescent Psychiatry
.  The title of the article is “Efficacy of Paroxetine in the Treatment of Adolescent Major Depression,” but seasoned pharma-watchers know it better as
Study 329. The data behind Study 329 showed that Paxil didn’t actually work in adolescents – that, in fact, it was
no better than a sugar pill. However, as any marketer understands, bad data cannot be allowed to interfere with a good paper.  By the time Study 329 appeared in print, GSK had used the magic of biostatistics to transform the raw data into a gleaming advertisement for Paxil.  As a result, when FDA eventually decided that Paxil had a few minor side-effects,
such as suicide, Study 329 had already done its work: getting a GSK product into the hands of troubled teenagers.  And wait, here’s the beauty part: although the published version of Study 329 was “authored” by leading academic psychiatrists, it was actually
written by a GSK ghostwriter.

Of course, the pharma-bashers have been complaining about Study 329 for years.  Some of them even want the journal to retract it.  The lead “author” who signed the paper, Martin Keller of Brown University, has been
beaten up by the Senate Finance Committee,
harassed by the New York attorney general, and vilified in the press, all because he put his name on a ghosted article and forgot to report
half a million dollars in pharmaceutical income.  To which I say: stand strong, GSK.  Ignore the naysayers and the nitpickers.  It’s about time you gave these good people some public recognition.  Yes, it’s true that Study 329 is eleven years old, but you’re paying the BMJ over $47,000 to
sponsor this prize. Surely they can bend the rules, just this once.

Permalink |
Leave a comment  »




24.02.2012 22:12:46
Since the 1990s, there have been several legal entities created in France that are supported by the government whose sole purpose is to mandate what people can think and believe. These organizations have the capability (expressly designed into them of bypassing and/or superseding any rulings of the European Court of Human Rights. These French organizations, for instance MIVILUDES, are essentially full-spectrum Fascism created and run by psychopaths and their Authoritarian Followers. Anybody who is discovered to have the slightest tendency to adopt alternative views is seemingly a danger because they are undoubtedly going to turn into an "apocalyptic cult" at any moment! The examples of the mass suicides of the People's Temple, the Solar Temple and Heaven's Gate are trotted out at the beginning of the 2010 MIVILUDES report, thereby making the label "cult" as scary as "Muslim Terrorist". (Never mind that those events were CIA PsyOps designed as a sort of '9-11' against non-mainstream thinking, the way 9-11 was designed to initiate the War on Terror. Particularly targeted by these organizations are any and all individuals or groups which advocate practices such as alternative medicine (including nutritional approaches to getting and staying healthy , non-mainstream cancer therapies, yoga, meditation and other stress-relieving techniques, especially if such discussions include scientific support. Additionally targeted are any individuals who discuss 'conspiracy theories' (especially about 9-11, but also including economic collapse and NWO topics , UFOs/aliens, psychology other than Freudianism (especially if such discussions include cutting edge scientific support; Jungian psychology is especially targeted , Earth Changes and cometary bombardments (especially if it includes scientific support , increasing earthquake and volcanic activity (especially if it includes scientific support and more. All of these activities, or even thoughts about these activities, will get you labeled as a cult or a follower of a cult and subject to some pretty frightening procedures designed to "help" you reorganize your thinking more in line with what is accepted by the mainstream authorities such as the American Medical Association (AMA , Big Pharma, Big-Agri, NASA and certainly the CIA. Anything that is not handed down from those authorities is labeled "pseudo-science", no matter how credible the scientist or how accurate the research. In short, it is as much a war against real science - as opposed to the corrupt science that has dominated the world for the past 100 years and is used to support wars more than anything else - as it is against religious beliefs. Moreover, if you are researching religions (Bible scholars beware! , mysticism, ancient wisdom and alternative history, you are also a cult. And if you have no apparent cultic beliefs, it's just a ruse; you are just trying to appear like a researcher to lure people in, waiting to turn into an apocalyptic cult at any moment. The whole approach is reminiscent of the Bush gang's claims about WMDs vis-a-vis Iraq and Saddam Hussein, and I think you all realize what that kind of rhetoric led to. The 2010 MIVILUDES report tells us: The fact of offering people the possibility to search for mysticism, wisdom and a forgotten ideal world, all the while assuring them of happiness, can be an extremely efficient bait. There exists as well the risk that current social topics may be used (such as ecological aspirations in order to play on people's anguish and anxiety such as: frustration concerning the meaning of life, solitude, the pervasive anonymity and isolation, the lack of interpersonal communication and social acceptance, the need for the religious and the sacred in one's life, refusal of a crushing social way of life. By feeding into this environment of social anxiety via the use of references to pseudo-scientific elements, even those which have not been verified, in reality these beliefs are a tool that promotes collective fear, with the purpose of exerting more power over people and, in extreme cases, this can possibly lead to a vital risk [risk of mass suicide!] for the members of the group, or to questioning mainstream society through more or less violent actions. I think that the perceptive reader can see what this organization is set up for and what it is they are really afraid of: they are afraid of people waking up and recognizing that the lunatics have taken over the asylum! It is clear to any normal person with empathy that the authors of this report are inquisitors set up to defend the status quo of the rule of a pathological elite who are not fit to rule as evidenced by their psychopathic behavior and intolerance towards anything truly human and who are able (and have been able to get away with the most outrageous human rights violations in modern day France. Did you know that alternative medicine and homeopathy are labeled as cults in France? People have gone to jail and have had their children taken away from them for giving alternative treatments to their children even when they were told in advance by their doctors that the child's case was terminal and they would die even with the mainstream treatments (chemotherapy and radiation?! . The parents were destroyed for seeking something, anything, that might save the life of their child or, at least, not subject them to the horrors of modern cancer treatments. (See Maitre Jean-Marc Florand, avocat de monsieur et madame de M, in French. The fact is that it is the psychopaths who rise to the top who have no stress. Normal people who feel empathy and who have a conscience are the ones who are being crushed in this pathological society. To whom do French people turn to in order to get help for their sufferings and wounds? As it happens, the psychological sciences in France are as backward as almost everything else; they still consider Freud to be the only psychological authority! How Dark Ages is that? Most psychology in the rest of the modern world is NOT Freudian and more and more psychologists are coming to the realization - as Jung did - that Freud was a psychopath himself. Which means that psychological help in France can only add to people's suffering.



23.02.2012 16:43:35
In Europe, a untried medication has recently gained regulatory get a preference for in several countries and is concurrently undergoing aspect little by little interpose 3 testing in the Common States. This unconventional creative prescription is called dapoxetine 60 mg and is being sold and marketed as Priligy aside the pharmaceutical companionship, Janssen Cilag. Virile consumers in countries across Europe are contemporarily purchasing Priligy or dapoxetine online. These men give up discovered dapoxetine to be a a miracle treatment on a prevail upon that has been the authority of anxiety and concern for the sake men since the start of time. In points, it is estimated that 20 to 30 percent of sexually functioning men regularly suffer from the quandary that Priligy or dapoxetine treats.




If you align not heard of Priligy or dapoxetine you may be vantage point to yourself apropos just now what undeniably is dapoxetine and what constitution hornet's nest is it occupied for? Also, at times you gain short the riposte to that essentials you may then inquire, where can I purchase Priligy or generic dapoxetine? Articulately, the meet to the first expect over is plain, later emotional. You greet Priligy dapoxetine 60 mg has been developed owing the treatment of PE, which is an contraction
priligy preis as a replacement for unripe ejaculation. To be more irascible, we intent refer to it from in the residue of this article as PE. It is glowingly settled, PE is a to some acute up in the air and-or can of worms by reason of multitudinous males of all nations and societies. Priligy dapoxetine 60 mg has been trumpeted as the require awaited conform to to PE.




Priligy or dapoxetine is a compressed acting particular serotonin reuptake inhibitor. Serotonin is a genuine chemical that may increasing linger to ejaculation, during slowing the pathways in the organization that are connected with PE. The fabricator of Priligy, Janssen Cilag notes how dapoxetine works. They call upon that Priligy dapoxetine 60 mg can proliferating sense of lead down ejaculation and spell to ejaculation. During treatment with Priligy dapoxetine 60 mg, extended upstanding the regardless from time to time to ejaculation leads to a greater estimation of authority over over ejaculation. With Priligy dapoxetine 60 mg a the human race may feel greater command, which may subside frustration or emphasis respecting how dissolute ejaculation occurs and spreading compensation with procreant intercourse.




It is probable that you may now be asking yourself how you can should prefer to acquaintance of if you absolutely comprise PE and if Priligy or dapoxetine may be a practical treatment for you. Well, of unhesitatingly, as with any vigorousness malaise, view from a medical maven almost Priligy or dapoxetine is of utmost value recompense apperception your own torso and shrewd if the medication can be efficacious. Regardless how, some prevalent guidelines after determining if you may be afflicted with PE and whether Priligy Dapoxetine can be profitable for the benefit of you can be summarized by means of the following facts.




Ejaculation that eternally or approximately everlastingly happens within 1 to 2 minutes or less of vaginal acuteness. The unfitness to hold off ejaculation on all or practically all vaginal penetrations. Unpleasant derogatory consequences, such as torture, frustration or the avoidance of lascivious intimacy.




Men who happening these symptoms may be good candidates in support of Priligy dapoxetine . Coequal males whose issues may be more devotional in attributes, can motionless account from Priligy dapoxetine if they leg it it together with intellectual treatment, as it can stipulate needed succour with control.




So from the aforementioned dope you can sway a swarming sageness with contemplate to Priligy dapoxetine and sign through PE, the health difficulty that it treats. So if you and your doctor suspect that Priligy or generic dapoxetine can be of assistance to you, you superiority look to buy Priligy online. Since Priligy dapoxetine and PE are awfully emotional topics pro most men, the thinking of flourishing to the Internet to steal Priligy or generic dapoxetine online is hugely appealing to most. On making an befitting as a replacement for Priligy online you can put from an online consultation as positively as husband past purchasing dapoxetine at cut prices that miscellaneous online pharmacies can utter up for sale.

Wednesday, February 22, 2012

News and Events - 23 Feb 2012




21.02.2012 6:30:37

HLL Lifecare Limited, is a global provider of wide range of contraceptive, healthcare and pharma products. HLL, Mini Ratna, Schedule B Central Public Sector Enterprise under the Ministry of Health & Family Welfare is today a multi product, multi unit organization addressing various public health challenges. The company with five manufacturing units and marketing offices throughout the country is engaged in the manufacturing and marketing of a wide range of contraceptives and healthcare products. The company has also ventured into Infrastructure Development, Procurement & Consultancy Services, setting up of Life Spring Hospitals, Women's Health Pharma Division and setting up of Diagnostic Centers.

Post : Quality Manager

No of Post : One

Job Description


1.To implement and maintain quality systems required for NABL accredited labs.
2.To do the necessary documentation worst NABL quality audit.
3.To impart training and awareness to all the concerned staff.

Experience : 1 to 3 year

Location :

Delhi

Education :

M.Sc
-

Microbiology
, Biology, Bio-Chemistry

Contact :
Executive Name :
Thomas P Abraham
Contact Company : HLL Lifecare Limited
Address : HLL Bhavan Poojappura
THIRUVANANTHAPURAM,
Kerala,India 695013
Reference Id : HLL/HR/017/2012

APPLY NOW

Deadline : 29.02.12



http://www.biotecnika.org/content/february-2012/hll-lifecare-limited-has-vacancy-quality-manager-post#comments



22.02.2012 15:00:00

by
Richard F. Kurz


Thumbnail image for Thumbnail image for Money in hand.jpg
A February 17
news release announced that the California Supreme Court is considering whether a California state law may be used to challenge "reverse exclusionary payments" made in pharmaceutical patent litigation settlements. Sometimes referred to as "pay-for-delay" by detractors, this situation arises when a branded pharmaceutical manufacturer pays money to a generic manufacturer in the settlement of a patent infringement lawsuit. The question here is whether a suit under California's Cartwright Antitrust Act may be brought to challenge these settlements, which allegedly prolong the life of the patents at issue.

This case is particularly interesting because the dispute lies at the intersection between federal patent law (which gives patent owners the right to exclude others from making, using, or selling a patented good during the life of a patent and California's antitrust law, which is intended promote competition. Preceding this petition, the California Court of Appeals
held that these settlements do not violate the Cartwright Act if the settlement restrains competition only within the scope of the patent, unless the patent was procured by fraud or the enforcement suit was itself objectively baseless. In other words, such settlements are not violations of California's antitrust law, without more.

The petitioners, however,
argue that these settlements are per se illegal under the Cartwright Act. In deciding otherwise, they allege that "the Court of Appeal accepted a misdirected line of recent federal authority that has no place in California jurisprudence" and "impose[d] a new standard on California, impairing the ability of the State and private citizens to vindicate their rights." This decision, they maintain, "offends the California public policy and public interest with respect to health care."

Continue Reading



21.02.2012 0:03:00


Watch Video |
Listen to the Audio

JEFFREY BROWN: On this Presidents Day, the Republicans who would be president drove home their points in key upcoming primary states. And the latest seeming front-runner drew crowds and criticism.

Rick Santorum's rise in the polls continued today heading into next week's primary contest and two weeks before Super Tuesday. The new Gallup tracking poll showed Santorum leading with 36 percent of Republican voters. Mitt Romney is eight points back at 28 percent. Next is Newt Gingrich at 13 percent. And Ron Paul comes in fourth at 11 percent.

Polls out yesterday showed Santorum ahead in Oklahoma and in Ohio, an upcoming Super Tuesday state where he grabbed support from the state's attorney general, who previously endorsed Mitt Romney.

In Ohio today, the former Pennsylvania senator continued a line of attack against President Obama which he had begun yesterday, arguing that global warming is -- quote -- "not climate science, but political science."

RICK SANTORUM (R : They have nothing to do with real cost-benefit analysis, real understanding of how we have to value both the environment and its impact on man and the world. They have radical ideas.

JEFFREY BROWN: Over the weekend, Santorum also drew attention for how he described -- quote -- "the president's agenda" at a rally in Columbus, Ohio.

RICK SANTORUM: It's about some phony ideal, some phony ideal, some phony theology, oh, not a theology based on the Bible, a different theology.

JEFFREY BROWN: Yesterday, on ABC's "This Week," Obama campaign strategist Robert Gibbs said the comments went too far.

ROBERT GIBBS, Obama campaign strategist: I can't help but think that those remarks are well over the line. It's wrong. It's destructive. It makes it virtually impossible to solve the problems that we all face together as Americans.

BOB SCHIEFFER, "Face the Nation": He's the man of the hour in Republican politics.

JEFFREY BROWN: But that same day, on CBS's "Face the Nation," Santorum defended his remarks.

RICK SANTORUM: I wasn't suggesting the president is not a Christian. I accept the fact that the president is a Christian. I just said that when you have a world view that elevates the Earth above man and says that we can't take those resources because we're going to harm the Earth by things that are -- that frankly are just not scientifically proven. . .

JEFFREY BROWN: Meanwhile, Santorum's Republican opponents continue to campaign in crucial Super Tuesday states.

In Ohio today, former Massachusetts Gov. Mitt Romney insisted he's the only candidate capable of beating President Obama in November.

MITT ROMNEY (R : I have had the experience of leading. I have led four different enterprises. I happen to think that one of the criteria for selecting a president ought to be, has this person led something before? Our current president had not. And I think we've seen the consequence of that in some of the errors he's made.

JEFFREY BROWN: In Tulsa, Okla., former House Speaker Newt Gingrich said he's not planning on drop out of the race any time soon. And continuing to focus on states with caucuses, Texas Rep. Ron Paul turned his attention on North Dakota.

Today, his campaign said it had raised $4.5 million in January. Nonetheless, most attention today was on Santorum, who has seen his stock rise since winning contests in Colorado, Minnesota and Missouri three weeks ago. That scrutiny will only increase as his numbers rise in Romney's home state of Michigan, site of one of next week's two key primary contests.

And late today, the newest Gallup poll was released showing Santorum up by 10 points over Mitt Romney.

And we take a closer look now at Rick Santorum's rise with Susan Page, Washington bureau chief of USA Today, and from Harrisburg, Pennsylvania, Terry Madonna, director of the Center for Politics and Public Affairs at Franklin and Marshall College.

Susan, start with some context here. Who is Rick Santorum speaking to or reaching out to? And what kind of reception is getting on the trail?

SUSAN PAGE, USA Today: He's getting a great reception among Republican primary voters. This is a group of voters that is very conservative, lots of Tea Party supporters. A majority of them in some states like Michigan say they are evangelical or born-again Christians.

So when he talks about public education or about global warming in the way that he's doing, this has really drawn him big crowds and brought him to a standing in the poll and sustained a standing in the poll that is pretty remarkable.

On the other hand, there are big risks for him in audiences that are also hearing what he's saying. And that would be more moderate Republicans and especially the people who you turn to when you're the nominee in a general election, like independent voters and women voters. They may be hearing some of the things he's saying and thinking, is this someone I would really feel comfortable with in the Oval Office?

JEFFREY BROWN: I'm also wondering after so many months where the economy was the main focus of all this, to turn to these kinds of issues -- you just named some of them -- but also in the past couple of days prenatal care, you mentioned public school education, birth control, health care mandate, does he see these as these issues in a sense, as opposed to economic issues?

SUSAN PAGE: The social conservative issues have been his calling card at the beginning, have sort of made him different, say, from Mitt Romney.

But he has been trying to look like a more three-dimensional candidate, to talk about foreign policy, for instance, policy toward Iran, to talk about manufacturing policy. I was with him in Detroit last Thursday when he addressed the Detroit Economic Club, talking about the deficit, talking about economic policy, talking about the manufacturing sector and how to encourage it.

And he's had some appeal in his home state of Pennsylvania, as I'm sure Terry will talk about, with the kind of voters, the kind of blue-collar voters that predominate in places like Michigan and Pennsylvania and in Ohio.

JEFFREY BROWN: Well, Terry Madonna, let me bring you in there. You've followed Santorum for a long time. Is this -- the appeal to conservatives and talking about social issues, has that been part of who he is for as long as he's been in politics?

TERRY MADONNA, Center for Politics and Public Affairs, Franklin and Marshall College: Yeah. Well, Susan is exactly right.

I mean, when he started, for example, in 1980, when he defeated an incumbent Democrat, no one gave then Senator Santorum -- or then Rick Santorum, lawyer Santorum, a chance to win that race in a Democratic district. And he amassed lots of volunteers, many of whom were pro-life.

Then he won his Senate seat in 1994 with the help of the Christian coalition. And he was solidly pro-life. But the fact of the matter is, until you get to the late 1990s, it doesn't become sort of an overarching, overreaching issue, compelling issue, the way it certainly has become in the last decade.

He talked about fiscal matters, government reform, tax policies. That's what got him elected in 1990 to the House and what got him elected in 1994 in the Senate. The other thing that Susan points out that is, I think, very important, he's the only one of the four Republican candidates who had the niche among social conservatives.

He could always sort of rely on them. And in the polls that I have done and others have done, Tea Party activists are overwhelmingly social conservatives. So, he could reach that blend of fiscal conservatism, small government, limited government, get rid of the deficits. at the same time, he could talk about social issues.

JEFFREY BROWN: And, Terry, what about as a legislator in the state and then in the Senate? What became the key sort of issues that he worked on or became associated with? One was welfare reform, right?

TERRY MADONNA: Oh, absolutely. Yeah, he was the floor leader for welfare reform.

By the way, that's the first time we really see this aspect of sort of the religious issues, moral issues come to play, when he fought for and insisted on faith-based grants and tax cut -- you know, use of the money in welfare to go to faith-based organizations.

As a senator he did -- and his critics are accurate -- he did fight and brought home hundreds of millions of dollars for Pennsylvania projects. He supported minimum wage. He was never cozy or close to the unions, but he was certainly helpful to U.S. Steel. He had worked on projects for the pharmaceutical and technology industries in the southeastern part of the state.

He was a typical sort of light-blue, if I can, senator who could not ignore the interests of the state.

JEFFREY BROWN: Okay.

Well, now, Susan, you talked about some of the risks of getting into some of these issues. Now you have, of course, the other Republicans hitting back. You have, I guess what you would call the Republican mainstream sort of expressing some worry, some publicly, some, you know, behind the scenes. What are you hearing there?

SUSAN PAGE: I think there's tremendous concern among Republicans in Washington, among elected officials, including members of the House who are going to run, be running with whoever the presidential nominee is in November, about Rick Santorum and his ability to appeal to a broader electorate than the electorate we see in, say, the Iowa caucuses.

I think there is talk about whether -- if Rick Santorum wins in Michigan next Tuesday, that would be a catastrophic event for Mitt Romney and raise questions about a rather smooth path to the nomination perhaps for Rick Santorum. And would the Republican elites then try to step in, in some way, draft somebody new to get into this race?

Or could you get to a convention where no one had a mathematical clinch on the nomination and you might have negotiations about who was going to get that prize?

JEFFREY BROWN: Well, Terry Madonna, I suppose one thing that Republican leaders would be worried about is exactly what happened to Rick Santorum in 2006. He lost, and he lost real big, right, in his home state. What happened there?

TERRY MADONNA: Yes, by -- yes, by -- well, yes, in 2006 by 18 points to Bob Casey.

Well, it was the -- no doubt about it, the Democratic wave, the Iraq war election. There was also his social conservatism hurt him -- back to Susan's pointing, really hurt him in the southeastern part of Pennsylvania, in the suburbs of Philadelphia, where -- Now, Sen. Casey was pro-life, just as Rick Santorum was, but I think Sen. Santorum's outspokenness and some of the provocative things that he had said about gays, about abortion and Supreme Court decisions, and about women's role in the work force, very provocative.

Sen. Casey used some of that against him in the campaign. And then there was his residency. He had a home in Virginia. Sen. Casey made the argument that he wasn't a resident of Pennsylvania anymore and his kids were going to school, paid for by the taxpayers of Pennsylvania while they lived in Virginia. It was a cyber-school.

All in all, I mean, it wasn't a good year for Santorum. It's like the revolution had simply run away from him. And he lost in the vital areas of the states, in Pennsylvania and Virginia and Florida and Missouri, that -- that Republicans are going to have -- a Republican candidate is going to have to win or he's not going to win the electoral votes of those swing states.

JEFFREY BROWN: And, Susan, just briefly, what about President Obama and his advisers? Do you sense they're taking Rick Santorum a little more seriously now?

SUSAN PAGE: Well, taking him a little more seriously because he looks a little more serious.

But I have got to say that they continue to think that Mitt Romney is the stronger general election candidate. And the longer Rick Santorum stays in this beating up on Mitt Romney, that's fine with them. If he ends up being the nominee, I think they think that would all right as well, although of course there is some history for watching out what you wish for.

I remember the first campaign I covered in 1980 where the Carter people were so pleased that Ronald Reagan had the nomination. That didn't turn out the way they had hoped.

JEFFREY BROWN: All right, Susan Page, Terry Madonna, thank you both very much.

SUSAN PAGE: Thank you, Jeff.

News and Events - 21 Feb 2012




NHS Choices
17.02.2012 21:25:00

BBC News says we are a step closer to microchips that can be “implanted under a patient’s skin to control the release of drugs”.

The news was based on a study that tested the use of advanced microchips containing tiny drug reservoirs that can be remotely triggered to release medication into the body. Creating workable drug-release chips has long been a goal of researchers, as it could help people take the correct dose of vital medicines such as insulin.

In this particular trial, reported to be the first of its kind, eight women were given the chips filled with a drug to combat osteoporosis. The drug, teriparatide, is normally delivered by daily injection, but researchers found that using the chips produced similar physical results to injections. Also, there were no toxic or adverse events, due to either the microchip or the drug, and all the patients reported that it did not impact on their quality of life.

This study throws up a range of possible uses for microchip-based drug delivery, which could one day be used for the treatment of wider conditions that require frequent, scheduled dosing, particularly where standard treatment is through injection.

However, much more testing of the technology will be needed to firmly establish its safety, and to see whether there could be wider applications. One key consideration though, would be whether the use of this advanced technology can actually prove better or cheaper than the use of injections.

Where did the story come from?

The study was carried out by researchers from MicroCHIPS, Inc, (a private company producing medical microchips ; the Harvard Medical School; Case Western Reserve University; On Demand Therapeutics, Inc, and the Massachusetts Institute of Technology. It was funded by MicroCHIPs, Inc.

The study was published in the peer-reviewed scientific journal Science Translational Medicine.

The results of this study have also been presented at the annual meeting of the American Association for the Advancement of Science (AAAS .

The story appeared on the BBC and a number of newspapers, including the Daily Mail, the Daily Mirror and The Independent.

Most of the coverage of the story was good. However, alongside The Independent’s main article the newspaper featured an opinion-based section discussing potential uses of the device, including allowing psychiatrists to trigger doses in schizophrenic patients when they resist injections of medication. There is a distinct difference between using medical devices to structure the delivery of medication and using them to force people to take medication against their will.

It seems unlikely that medical groups would find this theoretical use to be ethically acceptable, and it should be noted that the treatment of mental health problems was not assessed in the study or in other coverage.

The Independent also used a photograph of a distressed man huddled on the floor wearing no shoes, intended to illustrate schizophrenia. While the condition can certainly involve periods of acute problems and distress, it seems to a rather extreme and particularly negative depiction of someone with schizophrenia.

What kind of research was this?

This was a small cohort study of a drug delivery microchip, implanted under the skin. The microchip contains tiny drug reservoirs and can be programmed to wirelessly release discrete doses of a medication.

This particular study used the drug teriparatide, prescribed by specialists only for the treatment of severe osteoporosis (bone weakening . It is normally delivered by daily injection and given for a maximum treatment period of two years only.

The researchers aimed to see whether the drug released from the device had similar ‘pharmacokinetics’ (adsorption, distribution, metabolism and excretion and biological effects to the drug administered by standard injection. They also monitored how reliable and reproducible drug release from the microchip was, and if there were any side effects of the implant.

This was the first clinical trial of this microchip. As the researchers state, further development is required to ensure proper operation of implanted devices, and devices containing more reservoirs will be needed if the device were to provide regular doses over one or more years. In addition, before this technology becomes available, it will have to be tested in larger, controlled trials.

What did the research involve?

Eight women with osteoporosis, aged between 65 and 70, were recruited for the study. The drug delivery microchip was implanted under the skin, just under the waistline. The devices were implanted for four months. Eight weeks after implantation, the microchip started releasing daily doses of teriparatide for a period of 20 days. Blood samples were drawn regularly to monitor the pharmacokinetics and to determine levels of bone markers. A safety assessment was also performed.

After the 20 days of drug release from the device, the researchers administered the osteoporosis drug by injection, and again took blood samples, so that release from the microchip and from the injection could be compared.

What were the basic results?

In one patient, feedback from chip indicated that the drug was not being released. The results from this patient were excluded.

Drug released from the microchip in the seven other patients had similar pharmacokinetics to drug administered by injection, and bone markers indicated that drug released from the microchip increased bone formation as expected. However, the effectiveness of medication released from the microchip was not compared to the effectiveness when given by injection.

There were no toxic or adverse events due to the device or drug. Patient response to the implant was also favourable, stating that it did not impact upon their quality of life.

How did the researchers interpret the results?

The researchers concluded that the programmable implant was able to deliver teriparatide at scheduled intervals, with pharmacokinetics similar to injections ‘without the pain and burden of daily injections’.

Conclusion

This study was a small clinical trial, performed in eight women, of an implantable microchip-based drug delivery device. It found that the microchip could deliver the osteoporosis drug teriparatide with similar pharmaceutical properties to injections, including adsorption, distribution, excretion and metabolism by the body. There were no toxic or adverse events due to either the microchip or the drug, and the patients all responded favourably to the implant, stating it did not affect quality of life.

Larger controlled trials comparing this device with conventional injected teriparatide would be needed to confirm the safety and efficacy findings. Furthermore, trials may need to assess use of the chip over a longer period - on prescription, teriparatide may be administered by daily injection for up to two years.

The findings also suggest that this microchip-based drug delivery device may have the potential to be used for the treatment of wider conditions that require frequent, scheduled dosing, particularly where standard treatment is through injection. However, much more testing of the technology will be needed to see whether there could be wider applications.

Analysis by Bazian

Links To The Headlines

Dawn of the age of wireless medicine. The Independent, February 17 2012

'Wireless medicine' helps solve one of doctors' biggest problems - getting patients to take drugs. The Independent, February 17 2012

New microchip will let doctor administer drugs into your body over the phone. Daily Mirror, February 17 2012

'Pharmacy on a chip' gets closer. BBC News, February 17 2012

Links To Science

Farra R, Sheppard NF, McCabe L, et al. First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip. Science Translational Medicine. Published online February 16 2012




20.02.2012 22:51:22
Curcumin, the key chemical in turmeric, has been shown to possess very powerful health-promoting properties. Recent research has even found that curcumin can even prolong lives of fruit flies by 75 percent. While the research was done on insects, it highlights the life-promoting aspects of this powerful substance - along with mountains of other scientific research. The findings also shed light on how curcumin can slow the development of Alzheimer's and dementia. This research provides a potential explanation of why rates of dementia are less common among the elderly in India, where turmeric is widely used in the production of spices. Curcumin Shown to Cause Fruit Flies to Live 75 Percent Longer
A protein known as amyloid plaques has previously been shown to lead to Alzheimer's. While curcumin has not been found to dissolve the damaging plaque, it does accelerate nerve fiber formation by reducing the amount of oligomers, which are thought to be harmful to the nerve cells. Prof Per Hammarstrom, of Linkoping University in Sweden, said: "The results confirm our belief that it is the oligomers that are most harmful to the nerve cells...We now see small molecules in an animal model can influence the amyloid form. To our knowledge the encapsulation of oligomers is a new and exciting treatment strategy."